Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

@article{Flinn2014IdelalisibAS,
  title={Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.},
  author={Ian W Flinn and Brad S Kahl and John P. Leonard and Richard R. Furman and Jennifer R Brown and John C. Byrd and Nina D. Wagner-Johnston and Steve E Coutre and Don Michael Benson and Sissy Peterman and Yoonjin Cho and Heather Kay Webb and David M. Johnson and Albert S. Yu and Roger G. Ulrich and W. Robert Godfrey and Langdon Leforrest Miller and Stephen E Spurgeon},
  journal={Blood},
  year={2014},
  volume={123 22},
  pages={
          3406-13
        }
}
Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL). Patients had a median (range) age of 64 (32-91) years, 34 (53%) had bulky disease (≥1 lymph nodes ≥5 cm), and 37 (58%) had refractory disease. Patients had received a median (range) of 4 (1-10) prior therapies. Eight dose regimens of idelalisib were evaluated; idelalisib was taken once or twice daily continuously… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 98 CITATIONS, ESTIMATED 47% COVERAGE

Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Idelalisib in the management of lymphoma.

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Chemotherapy-free treatment in patients with follicular lymphoma.

  • Expert review of hematology
  • 2015
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity.

  • Leukemia & lymphoma
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

  • Averaged 13 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Bendamustine: rebirth of an old drug.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 1 EXCERPT

guidelines for lymphoma

NCCN. Treatmen
  • http:// www.nccn.org/component/content/article/1-latestnews/315-nccn-announces-new-treatmentguidelines-for-patients.html. Accessed October 22,
  • 2013
VIEW 2 EXCERPTS

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

  • Cancer control : journal of the Moffitt Cancer Center
  • 2012

Similar Papers

Loading similar papers…